Pharmacogenomics of the Triazole Antifungal Agent Voriconazole
- 21 June 2011
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (6) , 861-872
Abstract
Genetic polymorphisms in drug-metabolizing enzymes are frequently responsible for high variability in the pharmacokinetics of certain drugs leading to large variations in drug efficacy and adverse drug effects, or large ranges of the doses required for optimal drug efficacy. Voriconazole is a triazole antifungal agent which has been available for several years and has potent in vitro and in vivo activity against a broad spectrum of medically important pathogens, including Aspergillus, Cryptococcus and Candida. Voriconazole is extensively metabolized by the cytochrome P450 system with CYP2C19 being the major route for elimination. Thus, polymorphisms in the CYP2C19 gene have substantial impact on the pharmacokinetics of voriconazole and its interactions with other drugs. This article summarizes the current knowledge regarding CYP2C19 and discusses the influences of other drug-metabolizing enzymes and drug transporters on voriconazole disposition.Keywords
Funding Information
- Pfizer
This publication has 66 references indexed in Scilit:
- Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismEuropean Journal of Clinical Pharmacology, 2010
- Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazolesBritish Journal of Clinical Pharmacology, 2010
- Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17British Journal of Clinical Pharmacology, 2010
- Voriconazole Pharmacokinetics in Liver Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotypeBritish Journal of Clinical Pharmacology, 2009
- Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver MicrosomesDrug Metabolism and Disposition, 2008
- Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co‐administered in healthy female subjectsBritish Journal of Clinical Pharmacology, 2008
- Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese populationBritish Journal of Clinical Pharmacology, 2008
- Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male SubjectsAntimicrobial Agents and Chemotherapy, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006